Skip to main content

Fiscal Wizard · Single-issue tearsheet

RVPH / Jun 21, 2026 Run #7498

RVPH

Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

Composite verdict

F 14.6 / 100
Bearish setup · Reversal 7 drivers · 5 gates blocking
  • Money Flow Index
  • ADX DI Cross
  • Stochastic Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 366th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 16 signals100% Bear
Momentum Bearish 30Mean-reversion Bearish 26
  • Late-stage trendTrend signals have been live for 118 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

27.4 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Return on Capital Employed 0
P/B 75
Free Cash Flow Yield 0
Greenblatt ROC 3

Technicals Bearish

1.7 / 100

Bearish setup leads (Money Flow Index, ADX DI Cross, Stochastic Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Money Flow Index 11
ADX DI Cross 13
Stochastic Cross 17

Risk Gates

5 blocking 2 caution

5 guards active, 24 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for RVPH.